Transaction DateRecipientSharesTypePriceValue
17th September 2020Anthony L. Boral9,879Exercise of derivative$15.01$148,283.79
17th September 2020Anthony L. Boral10,227Exercise of derivative$8.80$89,997.60
17th September 2020Anthony L. Boral23,136Open or private sale$80.00$1,850,880.00
17th September 2020Nicholas Lydon500Open or private sale$80.00$40,000.00
17th September 2020Anthony L. Boral3,030Exercise of derivative$8.80$26,664.00
19th August 2020Jeffrey W. Albers11,403Open or private sale$75.34$859,102.02
19th August 2020Jeffrey W. Albers8,597Open or private sale$74.60$641,336.20
19th August 2020Jeffrey W. Albers20,000Exercise of derivative$8.80$176,000.00
17th August 2020Ariel Hurley700Open or private sale$75.00$52,500.00
17th August 2020Ariel Hurley700Exercise of derivative$1.87$1,309.00
Blueprint Medicines
Blueprint Medicines logo

Blueprint Medicines Corp. focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy in 2008.

Ticker: BPMC
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1597264
Employees: 383
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $289 M (0%)
Inventory, Net: $4 M (0%)
Assets, Current: $568 M (9%)
Property, Plant and Equipment, Net: $37 M (0%)
Other Assets, Noncurrent: $8 M (-18%)
Assets: $817 M (15%)
Accounts Payable, Current: $6 M (16%)
Accrued Liabilities, Current: $84 M (0%)
Liabilities, Current: $105 M (-1%)
Other Liabilities, Noncurrent: $9 M (9%)
Liabilities: $236 M (-2%)
Common Stock, Value, Issued: $54 Th (10%)
Common Stock, Shares, Issued: $54 M (10%)
Retained Earnings (Accumulated Deficit): $1 B (24%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $1 M (-55%)
Stockholders' Equity (Parent): $581 M (0%)
Liabilities and Equity: $817 M (15%)
Cost of Revenue: $127 Th (-15%)
Research and Development: $91 M (-48%)
Other Income, net: $2 M (-63%)